Abstract:Pathogenic variants in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified that increase the risk for developing Parkinson's disease in a dominantly inherited fashion. These pathogenic variants, of which G2019S is the most common, cause abnormally high kinase activity, and compounds that inhibit this activity are being pursued as potentially disease-modifying therapeutics. Because LRRK2 regulates important cellular processes, developing inhibitors that can selectively target the pathogenic variant while sparing normal LRRK2 activity could offer potential advantages in heterozygous carriers. We conducted a high-throughput screen and identified a single selective compound that preferentially inhibited G2019S-LRRK2. Optimization of this scaffold led to a series of novel, potent, and highly selective G2019S-LRRK2 inhibitors.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01243?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01243</a>.Compound 1 homology model (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_001.pdb">PDB</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_002.csv">CSV</a>)Kinase panel for compound 31 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_003.csv">CSV</a>)Crystal data for compound (R)-32; 1H NMR and HPLC traces for compounds 1, 4, 7, 19, 20, 21, 22, 23, 25, 26, 30, and 31; and table of geometric mean and geometric standard deviation of biochemical potency (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01243/suppl_file/jm0c01243_si_004.pdf">PDF</a>)This article has not yet been cited by other publications.

Selective Inhibitors of G2019S-LRRK2 Kinase Activity

Clinical and Functional Evidence for the Pathogenicity of the LRRK2 P.arg1067gln Variant

GSK 2578215 A ; A Potent and Highly Selective 2-Arylmethyloxy-5-substitutent-n-arylbenzamide LRRK 2 Kinase Inhibitor

Brain Penetrant LRRK2 Inhibitor.

Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain.

LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation

Discovery of potent LRRK2 inhibitors by ensemble virtual screening strategy and bioactivity evaluation

Identification of LRRK2 Inhibitors Through Computational Drug Repurposing.

Identification of Novel LRRK2 Inhibitors by Structure-Based Virtual Screening and Alchemical Free Energy Calculation.

Molecular Modeling Study on the Interaction Mechanism Between the LRRK2 G2019S Mutant and Type I Inhibitors by Integrating Molecular Dynamics Simulation, Binding Free Energy Calculations, and Pharmacophore Modeling.

Leucine-rich Repeat Kinase 2 Inhibitors: a Patent Review (2006 – 2011)

Characterization of a Selective Inhibitor of the Parkinson’s Disease Kinase LRRK2

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Decoding Inhibitor Egression from Wild-Type and G2019S Mutant LRRK2 Kinase: Insights into Unbinding Mechanisms for Precision Drug Design in Parkinson's Disease

Novel LRRK2 GTP-binding Inhibitors Reduced Degeneration in Parkinson's Disease Cell and Mouse Models.

Unveiling the Selectivity Mechanism of Type-I LRRK2 Inhibitors by Computational Methods: Insights from Binding Thermodynamics and Kinetics Simulation.

Multi-method computational evaluation of the inhibitors against leucine-rich repeat kinase 2 G2019S mutant for Parkinson's disease

Type-II kinase inhibitors that target Parkinson’s Disease-associated LRRK2

Progressive Dopaminergic Alterations and Mitochondrial Abnormalities in LRRK2 G2019S Knock-in Mice

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression

LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease